 SVT and one or more risk factors for VTE were
randomized to 45 days of fondaparinux or rivaroxaban
10 mg.257 The results suggested that rivaroxaban was as
effective as fondaparinux, however, the study was not
powered to prove noninferiority. A call for further studies
was prompted by the nonsigniÔ¨Åcant increase in the primary composite outcome as well as by an increase in
